PH12017501384A1 - Pharmaceutical compositions for combination therapy - Google Patents

Pharmaceutical compositions for combination therapy

Info

Publication number
PH12017501384A1
PH12017501384A1 PH12017501384A PH12017501384A PH12017501384A1 PH 12017501384 A1 PH12017501384 A1 PH 12017501384A1 PH 12017501384 A PH12017501384 A PH 12017501384A PH 12017501384 A PH12017501384 A PH 12017501384A PH 12017501384 A1 PH12017501384 A1 PH 12017501384A1
Authority
PH
Philippines
Prior art keywords
combination
agonist
ppar
present
prevention
Prior art date
Application number
PH12017501384A
Other languages
English (en)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017501384(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of PH12017501384A1 publication Critical patent/PH12017501384A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12017501384A 2015-02-06 2017-08-01 Pharmaceutical compositions for combination therapy PH12017501384A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06
PCT/US2016/016694 WO2016127019A2 (en) 2015-02-06 2016-02-05 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
PH12017501384A1 true PH12017501384A1 (en) 2018-01-08

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017501384A PH12017501384A1 (en) 2015-02-06 2017-08-01 Pharmaceutical compositions for combination therapy

Country Status (30)

Country Link
US (5) US11311557B2 (https=)
EP (2) EP4035665A1 (https=)
JP (2) JP7306791B2 (https=)
KR (1) KR20170115071A (https=)
CN (1) CN107405325B (https=)
AR (1) AR103624A1 (https=)
AU (2) AU2016215179B2 (https=)
BR (1) BR112017016766B1 (https=)
CA (1) CA2976056C (https=)
CL (3) CL2017001983A1 (https=)
CO (1) CO2017007959A2 (https=)
CR (1) CR20170356A (https=)
DK (1) DK3253382T3 (https=)
EA (1) EA036404B1 (https=)
EC (1) ECSP17057848A (https=)
ES (1) ES2905872T3 (https=)
GT (1) GT201700174A (https=)
IL (2) IL253719B (https=)
MA (1) MA40814A1 (https=)
MX (1) MX388508B (https=)
NI (1) NI201700100A (https=)
PE (1) PE20180027A1 (https=)
PH (1) PH12017501384A1 (https=)
SG (1) SG11201706347SA (https=)
SV (1) SV2017005512A (https=)
TN (1) TN2017000344A1 (https=)
TW (1) TW201628625A (https=)
UA (1) UA125744C2 (https=)
WO (1) WO2016127019A2 (https=)
ZA (1) ZA201706007B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201628625A (zh) 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
AU2016325619A1 (en) 2015-09-24 2018-04-12 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
HRP20250776T1 (hr) * 2016-03-31 2025-08-29 Genfit Elafibranor za uporabu u liječenju primarnog bilijarnog kolangitisa
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Limited composição farmacêutica e método para o tratamento de colangite biliar primária
KR20190117632A (ko) * 2017-02-21 2019-10-16 장피트 Ppar 효현제와 fxr 효현제의 병용
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113677336B (zh) * 2019-04-10 2024-04-30 基恩菲特公司 包含式(i)化合物和glp-1受体激动剂的组合疗法
CN114144185A (zh) * 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
KR20220035365A (ko) * 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
CA3154859A1 (en) * 2019-09-20 2021-03-25 Reneo Pharmaceuticals, Inc. Use of a ppar-delta agonist in the treatment of kidney disease
CN114929214A (zh) * 2019-11-22 2022-08-19 阿沃林特有限公司 Sglt2抑制剂治疗原发性胆汁性胆管炎的用途
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
WO2022043367A1 (en) 2020-08-26 2022-03-03 Genfit Compositions and methods for the treatment of primary biliary cholangitis
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
US20250161326A1 (en) * 2022-01-28 2025-05-22 Intercept Pharmaceuticals, Inc. Combination therapy
EP4583874A1 (en) * 2022-12-21 2025-07-16 Charles University, Faculty Of Pharmacy In Hradec Kralove Multitarget nuclear receptor ligands based on 2-(4-(quinolin-2-yloxy)phenoxy)propanoic acid and 2-(4-(quinoxalin-2-yloxy)phenoxy)propanoic acid for the treatment of metabolic and liver diseases
WO2025250918A1 (en) * 2024-05-30 2025-12-04 Intercept Pharmaceuticals, Inc. Novel compositions
EP4725479A1 (en) 2024-10-09 2026-04-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Ppar agonists for treatment of diseases associated with aatd

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (https=) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FI52570C (fi) 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (https=) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (https=) 1973-07-05 1977-07-15 Roussel Uclaf
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
CA2110095A1 (en) 1992-12-08 1994-06-09 Teruo Komoto Arylamide derivatives
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1998032444A1 (en) 1997-01-24 1998-07-30 The Regents Of The University Of California USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION
HN1998000124A (es) * 1997-08-29 1999-02-09 Pfizer Prod Inc Terapia de combinacion
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
CA2355820A1 (en) 1998-12-18 2000-06-29 Abbott Laboratories Novel formulations comprising lipid-regulating agents
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
WO2000040965A1 (en) 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
NZ522036A (en) 2000-04-19 2004-04-30 Borody Thomas J Compositions and therapies for hyperlipidaemia-associated disorders
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
JP2004509161A (ja) 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
ES2248581T3 (es) 2001-03-12 2006-03-16 Intercept Pharmaceuticals, Inc. Esteroides como agonistas de fxr.
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
GB0405349D0 (en) * 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
WO2007111992A2 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
TW200812982A (en) 2006-05-24 2008-03-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101448791B (zh) 2006-05-24 2011-11-16 伊莱利利公司 Fxr激动剂
US7932244B2 (en) * 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
AU2006346853A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Drug formulation containing fibrate medicament and process for producing the same
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EA020849B1 (ru) * 2009-11-26 2015-02-27 Женфит Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
SI3336097T1 (sl) 2012-06-19 2021-07-30 Intercept Pharmaceuticals, Inc. Priprava nekristalinične oblike obetiholne kisline
SG11201503247UA (en) 2012-10-26 2015-06-29 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
TN2015000497A1 (en) * 2013-05-14 2017-04-06 Intercept Pharmaceuticals Inc 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
TW201628625A (zh) 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
CN114144185A (zh) 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物

Also Published As

Publication number Publication date
MA40814A1 (fr) 2019-08-30
JP7306791B2 (ja) 2023-07-11
EP3253382A4 (en) 2018-10-31
BR112017016766B1 (pt) 2023-11-07
JP2018504438A (ja) 2018-02-15
US11311557B2 (en) 2022-04-26
HK1246191A1 (zh) 2018-09-07
EP3253382A2 (en) 2017-12-13
CA2976056A1 (en) 2016-08-11
US20180008616A1 (en) 2018-01-11
CN107405325A (zh) 2017-11-28
ECSP17057848A (es) 2017-10-31
DK3253382T3 (da) 2022-02-14
JP2022000483A (ja) 2022-01-04
MX388508B (es) 2025-03-20
MX2017010131A (es) 2017-11-01
US20250367217A1 (en) 2025-12-04
CA2976056C (en) 2024-02-06
KR20170115071A (ko) 2017-10-16
ES2905872T3 (es) 2022-04-12
TW201628625A (zh) 2016-08-16
NI201700100A (es) 2018-09-06
CL2018003604A1 (es) 2019-02-22
SV2017005512A (es) 2018-06-12
BR112017016766A2 (en) 2018-04-10
US20220280534A1 (en) 2022-09-08
TN2017000344A1 (en) 2019-01-16
WO2016127019A2 (en) 2016-08-11
CR20170356A (es) 2018-02-28
GT201700174A (es) 2018-11-13
IL290823A (en) 2022-04-01
CO2017007959A2 (es) 2017-10-31
EA201791770A1 (ru) 2017-12-29
SG11201706347SA (en) 2017-09-28
PE20180027A1 (es) 2018-01-09
IL253719A0 (en) 2017-09-28
CL2017001983A1 (es) 2018-04-20
ZA201706007B (en) 2019-01-30
WO2016127019A3 (en) 2016-11-03
CN107405325B (zh) 2021-11-12
EA036404B1 (ru) 2020-11-06
EP3253382B1 (en) 2021-11-17
AU2016215179B2 (en) 2021-02-25
CL2018001006A1 (es) 2018-06-15
EP4035665A1 (en) 2022-08-03
AR103624A1 (es) 2017-05-24
IL253719B (en) 2022-04-01
AU2021201015A1 (en) 2021-03-11
US12337003B2 (en) 2025-06-24
US20220280533A1 (en) 2022-09-08
US20250367216A1 (en) 2025-12-04
UA125744C2 (uk) 2022-06-01
AU2016215179A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
PH12017501384A1 (en) Pharmaceutical compositions for combination therapy
MX2018005096A (es) Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
AU2018246796A1 (en) S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
EA201592020A1 (ru) Новая композиция для неалкогольной жировой болезни печени (нажбп)
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
MX2021014585A (es) Composiciones farmaceuticas que comprenden un agonista de fxr y un fibrato para usarse en el tratamiento de la enfermedad hepatica colestatica.
HK1247850A1 (zh) Pd-1 拮抗剂与egfr 抑制剂的组合
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
WO2007111992A3 (en) Methods and compositions for treating hypercholesterolemia and atherosclerosis
EP4674862A3 (en) Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
MX2021002305A (es) Tratamiento de trastornos del higado.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
AU2020258568A8 (en) CD73 inhibitors
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
WO2017040407A8 (en) Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
EP4234536A3 (en) Amino-aryl-benzamide compounds and methods of use thereof
EP3718552A4 (en) APPROPRIATE DRUG COMBINATION FOR THE TREATMENT AND PREVENTION OF NON-ALCOHOLIC HEPATIC STEATOSIS (NAFLAD) AND / OR NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND / OR HEPATIC STEATOSIS
WO2021041561A3 (en) Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
AU2020378127A8 (en) Compounds as CD73 inhibitors
WO2009148600A8 (en) Deuterated lysine-based compounds
MX2025003004A (es) Formas farmaceuticas de un inhibidor de cd73